Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Exosomes harbor B cell targets in pancreatic adenocarcinoma and exert decoy function against complement-mediated cytotoxicity.

Capello M, Vykoukal JV, Katayama H, Bantis LE, Wang H, Kundnani DL, Aguilar-Bonavides C, Aguilar M, Tripathi SC, Dhillon DS, Momin AA, Peters H, Katz MH, Alvarez H, Bernard V, Ferri-Borgogno S, Brand R, Adler DG, Firpo MA, Mulvihill SJ, Molldrem JJ, Feng Z, Taguchi A, Maitra A, Hanash SM.

Nat Commun. 2019 Jan 16;10(1):254. doi: 10.1038/s41467-018-08109-6.

2.

Autoantibody signature in human ductal pancreatic adenocarcinoma.

Tomaino B, Cappello P, Capello M, Fredolini C, Ponzetto A, Novarino A, Ciuffreda L, Bertetto O, De Angelis C, Gaia E, Salacone P, Milella M, Nisticò P, Alessio M, Chiarle R, Giuffrida MG, Giovarelli M, Novelli F.

J Proteome Res. 2007 Oct;6(10):4025-31. Epub 2007 Sep 8.

PMID:
17824682
3.

Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients.

Castillo J, Bernard V, San Lucas FA, Allenson K, Capello M, Kim DU, Gascoyne P, Mulu FC, Stephens BM, Huang J, Wang H, Momin AA, Jacamo RO, Katz M, Wolff R, Javle M, Varadhachary G, Wistuba II, Hanash S, Maitra A, Alvarez H.

Ann Oncol. 2018 Jan 1;29(1):223-229. doi: 10.1093/annonc/mdx542.

4.

Saliva exosomes from pancreatic tumor-bearing mice modulate NK cell phenotype and antitumor cytotoxicity.

Katsiougiannis S, Chia D, Kim Y, Singh RP, Wong DT.

FASEB J. 2017 Mar;31(3):998-1010. doi: 10.1096/fj.201600984R. Epub 2016 Nov 28.

5.

An integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma-associated antigen.

Cappello P, Tomaino B, Chiarle R, Ceruti P, Novarino A, Castagnoli C, Migliorini P, Perconti G, Giallongo A, Milella M, Monsurrò V, Barbi S, Scarpa A, Nisticò P, Giovarelli M, Novelli F.

Int J Cancer. 2009 Aug 1;125(3):639-48. doi: 10.1002/ijc.24355.

6.

Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models.

Capello M, Cappello P, Linty FC, Chiarle R, Sperduti I, Novarino A, Salacone P, Mandili G, Naccarati A, Sacerdote C, Beghelli S, Bersani S, Barbi S, Bassi C, Scarpa A, Nisticò P, Giovarelli M, Vineis P, Milella M, Novelli F.

J Hematol Oncol. 2013 Sep 6;6:67. doi: 10.1186/1756-8722-6-67.

7.

No evidence of pancreatic ductal adenocarcinoma specific autoantibodies to Ezrin in a liquid phase LIPS immunoassay.

Liberati D, Marzinotto I, Brigatti C, Dugnani E, Pasquale V, Reni M, Balzano G, Falconi M, Piemonti L, Lampasona V.

Cancer Biomark. 2018;22(2):351-357. doi: 10.3233/CBM-181218.

PMID:
29660901
8.

An autoantibody-mediated immune response to calreticulin isoforms in pancreatic cancer.

Hong SH, Misek DE, Wang H, Puravs E, Giordano TJ, Greenson JK, Brenner DE, Simeone DM, Logsdon CD, Hanash SM.

Cancer Res. 2004 Aug 1;64(15):5504-10.

9.

Novel tumor marker REG4 detected in serum of patients with resectable pancreatic cancer and feasibility for antibody therapy targeting REG4.

Takehara A, Eguchi H, Ohigashi H, Ishikawa O, Kasugai T, Hosokawa M, Katagiri T, Nakamura Y, Nakagawa H.

Cancer Sci. 2006 Nov;97(11):1191-7. Epub 2006 Aug 17.

10.

Circulating autoantibodies to phosphorylated α-enolase are a hallmark of pancreatic cancer.

Tomaino B, Cappello P, Capello M, Fredolini C, Sperduti I, Migliorini P, Salacone P, Novarino A, Giacobino A, Ciuffreda L, Alessio M, Nisticò P, Scarpa A, Pederzoli P, Zhou W, Petricoin Iii EF, Liotta LA, Giovarelli M, Milella M, Novelli F.

J Proteome Res. 2011 Jan 7;10(1):105-12. doi: 10.1021/pr100213b. Epub 2010 Jun 10.

11.

A microRNA signature in circulating exosomes is superior to exosomal glypican-1 levels for diagnosing pancreatic cancer.

Lai X, Wang M, McElyea SD, Sherman S, House M, Korc M.

Cancer Lett. 2017 May 1;393:86-93. doi: 10.1016/j.canlet.2017.02.019. Epub 2017 Feb 20.

12.

High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients.

Allenson K, Castillo J, San Lucas FA, Scelo G, Kim DU, Bernard V, Davis G, Kumar T, Katz M, Overman MJ, Foretova L, Fabianova E, Holcatova I, Janout V, Meric-Bernstam F, Gascoyne P, Wistuba I, Varadhachary G, Brennan P, Hanash S, Li D, Maitra A, Alvarez H.

Ann Oncol. 2017 Apr 1;28(4):741-747. doi: 10.1093/annonc/mdx004.

13.

Profiling the potential tumor markers of pancreatic ductal adenocarcinoma using 2D-DIGE and MALDI-TOF-MS: up-regulation of Complement C3 and alpha-2-HS-glycoprotein.

Chen J, Wu W, Chen L, Zhou H, Yang R, Hu L, Zhao Y.

Pancreatology. 2013 May-Jun;13(3):290-7. doi: 10.1016/j.pan.2013.03.010. Epub 2013 Mar 15.

PMID:
23719603
14.

Tumor-Secreted Exosomal miR-222 Promotes Tumor Progression via Regulating P27 Expression and Re-Localization in Pancreatic Cancer.

Li Z, Tao Y, Wang X, Jiang P, Li J, Peng M, Zhang X, Chen K, Liu H, Zhen P, Zhu J, Liu X, Liu X.

Cell Physiol Biochem. 2018;51(2):610-629. doi: 10.1159/000495281. Epub 2018 Nov 20.

15.

Monitoring and functional characterization of the lymphocytic compartment in pancreatic ductal adenocarcinoma patients.

Oberg HH, Grage-Griebenow E, Adam-Klages S, Jerg E, Peipp M, Kellner C, Petrick D, Gonnermann D, Freitag-Wolf S, Röcken C, Sebens T, Vogel I, Becker T, Ebsen M, Kabelitz D, Wesch D, Sebens S.

Pancreatology. 2016 Nov - Dec;16(6):1069-1079. doi: 10.1016/j.pan.2016.07.008. Epub 2016 Jul 11.

PMID:
27424476
16.

Immune-complex level of cofilin-1 in sera is associated with cancer progression and poor prognosis in pancreatic cancer.

Satoh M, Takano S, Sogawa K, Noda K, Yoshitomi H, Ishibashi M, Mogushi K, Takizawa H, Otsuka M, Shimizu H, Miyazaki M, Nomura F.

Cancer Sci. 2017 Apr;108(4):795-803. doi: 10.1111/cas.13181.

17.

Dysbindin as a novel biomarker for pancreatic ductal adenocarcinoma identified by proteomic profiling.

Guo X, Lv X, Fang C, Lv X, Wang F, Wang D, Zhao J, Ma Y, Xue Y, Bai Q, Yao X, Chen Y.

Int J Cancer. 2016 Oct 15;139(8):1821-9. doi: 10.1002/ijc.30227. Epub 2016 Jun 30. Erratum in: Int J Cancer. 2017 Jul 15;141(2):E5.

18.

MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma.

Mikamori M, Yamada D, Eguchi H, Hasegawa S, Kishimoto T, Tomimaru Y, Asaoka T, Noda T, Wada H, Kawamoto K, Gotoh K, Takeda Y, Tanemura M, Mori M, Doki Y.

Sci Rep. 2017 Feb 15;7:42339. doi: 10.1038/srep42339.

19.

Identification of antibody reactive proteins in pancreatic cancer using 2D immunoblotting and mass spectrometry.

Rezaei M, Nikeghbalian S, Mojtahedi Z, Ghaderi A.

Oncol Rep. 2018 May;39(5):2413-2421. doi: 10.3892/or.2018.6285. Epub 2018 Feb 28.

PMID:
29498409
20.

Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver.

Costa-Silva B, Aiello NM, Ocean AJ, Singh S, Zhang H, Thakur BK, Becker A, Hoshino A, Mark MT, Molina H, Xiang J, Zhang T, Theilen TM, García-Santos G, Williams C, Ararso Y, Huang Y, Rodrigues G, Shen TL, Labori KJ, Lothe IM, Kure EH, Hernandez J, Doussot A, Ebbesen SH, Grandgenett PM, Hollingsworth MA, Jain M, Mallya K, Batra SK, Jarnagin WR, Schwartz RE, Matei I, Peinado H, Stanger BZ, Bromberg J, Lyden D.

Nat Cell Biol. 2015 Jun;17(6):816-26. doi: 10.1038/ncb3169. Epub 2015 May 18.

Supplemental Content

Support Center